Page 145 - 2020_01-Haematologica-web

STAT5 and IL-6 dysregulation in mastocytosis
34. Chang Q, Daly L, Bromberg J. The IL-6 feed- forward loop: a driver of tumorigenesis. Semin Immunol. 2014;26(1):48-53.
35. Yoon S, Woo SU, Kang JH, et al. NF-kappaB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene. 2012; 31(29):3467-3481.
36. Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators. Immunity. 2017; 46(2):220-232.
37. Barnstein BO, Li G, Wang Z, et al. Stat5 expression is required for IgE-mediated mast cell function. J Immunol. 2006; 177(5):3421- 3426.
38. Teodosio C, Garcia-Montero AC, Jara- Acevedo M, et al. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. J Allergy Clin Immunol. 2013;131(4):1213-1224.
39. Baumgartner C, Cerny-Reiterer S, Sonneck K, et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocyto- sis: subcellular distribution and role of the
transforming oncoprotein KIT D816V. Am J
Pathol. 2009;175(6):2416-2429.
40. Decker T, Kovarik P. Serine phosphorylation
of STATs. Oncogene. 2000; 19(21):2628-2637. 41. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link.
Cancer Cell. 2009;15(2):79-80.
42. Kawashima T, Murata K, Akira S, et al.
STAT5 induces macrophage differentiation of M1 leukemia cells through activation of IL-6 production mediated by NF-kappaB p65. J Immunol. 2001;167(7):3652-3660.
43. Xu R, Nelson CM, Muschler JL, Veiseh M, Vonderhaar BK, Bissell MJ. Sustained activa- tion of STAT5 is essential for chromatin remodeling and maintenance of mammary- specific function. J Cell Biol. 2009;184(1): 57- 66.
44. Bibi S, Arslanhan MD, Langenfeld F, et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of thera- py. Haematologica. 2014;99(3):417-429.
45. Shelburne CP, McCoy ME, Piekorz R, et al. Stat5 expression is critical for mast cell development and survival. Blood. 2003;
102(4):1290-1297.
46. Nievergall E, Reynolds J, Kok CH, et al.
TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016;30(6): 1263-1272.
47. Welner RS, Amabile G, Bararia D, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015;27(5):671-681.
48. Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421-3429.
49. Friedbichler K, Kerenyi MA, Kovacic B, et al. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transforma- tion. Blood. 2010;116(9):1548-1558.
50. Pircher TJ, Petersen H, Gustafsson JA, Haldosen LA. Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol Endocrinol. 1999;13(4):555-565.
haematologica | 2020; 105(1)
135